P-48 evaluation of il-1β and il-1ra in patients with chronic liver diseases

Introduction and Objectives: IL-1β is a proinflammatory key cytokine that participates in the progression of liver disease. Its antagonist IL-1RA mediates damage limitation; its increase is associated with positive effects on chronic liver diseases. This study aimed to evaluate the concentration of IL-1β and IL-1RA in subjects with alcoholic liver disease (ALD), chronic hepatitis C (CHC) and non-alcoholic fatty liver disease (NAFLD). Materials and Methods: A cross-sectional and multicenter study was carried out, which included alcoholic subjects (OH), alcoholic cirrhosis (CiOH) and alcoholic hepatitis (HA); patients with CHC and NAFLD were compared against subjects without criteria for alcohol drinking habits (CT). IL-1β and IL-1RA were quantified by Multiplex-MERCK©. For statistical analysis, SPSS V.22 were used, Mann-Whitney U, p<0.05; values expressed as mean ± standard error. Results: The groups included were: 18 (OH), 25 (CiOH), 14 (HA), 55 (CHC), 22 (NAFLD) and 81 (CT). IL-1β results (pg/mL): 13.8±9.2, OH; 4.4±1.7, CiOH; 3.05±0.05, HA; 7.1±2.3, CHC; 5±2, NAFLD and 3.2±0.1, CT. With differences in HA vs. CHC. For IL-1RA (pg/mL) 83.5±30, OH; 100.4±53.5, CiOH; 85±38.3, HA; 74.4±2, CHC; 316±203, NAFLD and 13.02±4.4, CT. With differences in CHC and NAFLD vs. CT and CiOH vs. CHC. Conclusions: IL-1β was 2.3 times increased in HA/CHC, which highlights the effect on exacerbating the inflammatory response in acute over chronic alcohol damage; IL-1RA that inhibits the activities of IL-1β increase may have protective effects on liver injury. IL-1RA is a protein that limits inflammation in liver disease, especially in non-alcoholic fatty liver disease, alcoholic cirrhosis, and chronic hepatitis C.Funding: This work was partially financed by CONACyT SALUD-2016-272579 and PAPIIT- UNAM TA200515